Combating Drug-Resistant Bacteria:  Small Molecule Mimics of Plasmid Incompatibility as Antiplasmid Compounds

Johna C. B. DeNap, Jason R. Thomas, Dinty J. Musk, and Paul J. Hergenrother*
Department of Chemistry, Roger Adams Laboratory, University of Illinois, Urbana, Illinois 61801
J. Am. Chem. Soc., 2004, 126 (47), pp 15402–15404
DOI: 10.1021/ja044207u
Publication Date (Web): November 5, 2004
Copyright © 2004 American Chemical Society
*

In papers with more than one author, the asterisk indicates the name of the author to whom inquiries about the paper should be addressed.

, hergenro@uiuc.edu

Abstract

Abstract Image

A major mechanism for bacterial resistance to antibiotics is through the acquisition of a plasmid coding for resistance-mediating proteins. Described herein is a strategy to eliminate these plasmids from bacteria, thus resensitizing the bacteria to antibiotics. This approach involves mimicking a natural mechanism for plasmid elimination, known as plasmid incompatibility. The compound apramycin was identified as a tight binder to SLI RNA (Kd = 93 nM), the in vivo target of the plasmid incompatibility determinate RNA I, and footprinting/mutagenesis studies indicate apramycin binds SLI in the important regulatory region that dictates plasmid replication control and incompatibility. In vivo studies demonstrate that this compound causes significant plasmid loss and resensitizes bacteria to conventional antibiotics. The demonstration that a small molecule can mimic incompatibility, cause plasmid elimination, and resensitize bacteria to antibiotics opens up new targets for antibacterial research.

Tools

History

  • Published In Issue December 01, 2004
  • Received September 23, 2004

Recommend & Share

Related Content

Other ACS content by these authors: